Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event
In a cohort study of 8 patients (aged 50−72 years) with chronic lung allograft dysfunction (CLAD) after lung transplantation (LTX), 4 patients [ages and sexes not stated] were described, who developed viral infection with parainfluenza, coronavirus or rhinovirus, infection with Rasamsonia argillacea and Mycobacterium fortuitum or Pseudomonas tracheobronchitis following treatment with alemtuzumab for CLAD1 .
All the patients, who had undergone LTX, had obstructive CLAD phenotype with rapid loss of lung function. They received a single dose of SC alemtuzumab 30mg for CLAD, and they were scheduled to receive prophylaxis with valganciclovir and unspecified azole for at least 6 months after the alemtuzumab therapy. However, they developed clinically symptomatic infections secondary to alemtuzumab. Two patients developed community-acquired respiratory viral infections due to parainfluenza and coronavirus on two separate occasions (n=1) and rhinovirus (n=1). One patient developed Pseudomonas tracheobronchitis, and 1 patient developed new parenchymal opacities due to infection with Rasamsonia argillacea and Mycobacterium fortuitum [times to reaction onsets and outcomes of ADRs not stated].
Footnotes
Country of occurrence, reporter country and primary source country not stated. Unable to contact author. Part of the abstracts presented at CHEST 2020 Annual Meeting, 18−21 October 2020.
Reference
- Girgis R, et al. ALEMTUZUMAB FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION. Chest 158 (Spec. issue): A2388, No. 4, Oct 2020. Available from: URL: 10.1016/j.chest.2020.08.2027 [abstract] [DOI]